On December 7th, the company announced the results of NeuVax's Phase 1/2 Trials and the initiation of Phase 3 trials which will be conducted at numerous testing centers throughout the United States.
According to the company's press release, NeuVax™ "exhibited an excellent safety and tolerability profile, and demonstrated a durable response out to 60 months". Included in the company's safety and tolerability profile were the 24-month and 60-month Landmark Analysis figures which highlighted the time frame NeuVax patients were disease-free versus those on the control arm. "Galena's 24-month Landmark Analysis noted that 94.3% of NeuVax patients were disease-free versus 86.8% of patients on the control arm (p=0.08) and the company's 60-month Landmark Analysis noted that 89.7% of NeuVax patients remain disease-free versus 80.3% of patients on the control arm (p=0.077)-a recurrence reduction of 47.7% among all patients at any dose. Multiple dose response analyses underscore the efficacy of the vaccine with statistical significance being achieved among the optimally-dosed and boosted patients".
Taken from the newly-posted SA article titled "Galena Biopharma Now Offers Considerable Long-Term Potential"